Forgot to highlight this paragraph => "Although it’s losing...

Forgot to highlight this paragraph => "Although it’s losing market share to Axiron, Androgel, the TRT market leader enjoying a 65% market share, loses patent protection in 2016. A month’s supply of either product costs $300-$350, or $50 with health insurance. So Axiron’s safety advantage is a necessary differentiator if it’s to avoid price pressure when TRT generics hit the market."

From memory, doesn't Axiron have something like a mere 14% market share; which they achieved from a scratch start three years ago?  If they have a safer product then why would their market share not grow more rapidly as a results of these recent developments?  In a perverse sort of what these recent adverse market developments may result in Axiron becoming the dominant treatment far faster than they could otherwise?  That may translate into a quadrupling of their current market share; which when combined with growth from other markets around the world should make for steady growth in earnings; despite the eventual launch of some generics post the patent expire of Androgel and less off label use.